MLND Key Statistics, Chart & Performance
The current stock price of MLND is 1.06 null. In the past month the price decreased by -7.02%. In the past year, price decreased by -41.44%.
MLND Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About MLND
Company Profile
Millendo Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Ann Arbor, Michigan. The company went IPO on 2012-10-04. Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The firm is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs are TPST-1495 and TPST-1120. The firm's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Company Info
Millendo Therapeutics Inc
Ann Arbor MICHIGAN 48104 US
CEO: Louis Arcudi
Phone: 17348459000.0
Millendo Therapeutics Inc / MLND FAQ
What does Millendo Therapeutics Inc do?
Millendo Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Ann Arbor, Michigan. The company went IPO on 2012-10-04. Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The firm is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs are TPST-1495 and TPST-1120. The firm's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
What is the current price of MLND stock?
The current stock price of MLND is 1.06 null. The price decreased by -5.36% in the last trading session.
Does Millendo Therapeutics Inc pay dividends?
MLND does not pay a dividend.
What is the ChartMill rating of Millendo Therapeutics Inc stock?
MLND has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
MLND Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MLND. When comparing the yearly performance of all stocks, MLND is a bad performer in the overall market: 98.82% of all stocks are doing better.
MLND Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MLND. MLND has a bad profitability rating. Also its financial health evaluation is rather negative.
MLND Financial Highlights
Over the last trailing twelve months MLND reported a non-GAAP Earnings per Share(EPS) of -1.73. The EPS increased by 44.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -103.44% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
MLND Forecast & Estimates
0 analysts have analysed MLND and the average price target is 2.04 null. This implies a price increase of 92.45% is expected in the next year compared to the current price of 1.06.